1Maggio R, Scarselli M, Novi F, et al. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole [J]. J Neurochem, 2003,87 (3) :631-641.
2Okura T, Ito T, Ishiguro N, et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist [J]. Life Sciences, 2007,80 (17) : 1564-1571.
3Parkison Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group [J]. JAMA, 2000,284(15):1931-198.
4Noyes K, Dick A W, Holloway R G. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life [ J ]. Value Health, 2006,9 ( 1 ) : 28- 38.
5Constantinescu R, Romer M, McDermott M P, et al. Impact of pramipexole on the onset of levodopa-related dyskinesias[J]. Mov Disord, 2007,22(9) : 1317-1319.
6Parkison Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage[J]. Clin Neuropharmacol, 2007,30(2) :72-85.
7Moller J C, Oertel W H, Koster J, et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial [ J ]. Mov Disord, 2005,20 (5) : 602- 610.
8Weiner W J, Factor S A, Jankovic J, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease [J]. Parkinsonism Relat Disord, 2001,7(2) : 115-120.
9Zanettini R, Antonini A, Gatto G, et al. Valvular Heart Disease and the Use of Dopamine Agonists for Parkiuson's Disease [J]. N Engl J Med, 2007,356( 1 ) : 39-46.
10Linazasoro G. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson's disease [ J ]. J Neurol, 2004,251 (3) : 335-339.
